Total Asset Turnover
since 2005
Paying user area
Try for free
Johnson & Johnson pages available for free this week:
- Statement of Comprehensive Income
- Analysis of Liquidity Ratios
- Analysis of Solvency Ratios
- Analysis of Long-term (Investment) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value to FCFF (EV/FCFF)
- Price to FCFE (P/FCFE)
- Return on Equity (ROE) since 2005
- Current Ratio since 2005
- Debt to Equity since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Johnson & Johnson for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Johnson & Johnson, total asset turnover, long-term trends, calculation
| Total asset turnover | = | Sales to customers1 | ÷ | Total assets1 | |
|---|---|---|---|---|---|
| Dec 29, 2024 | = | ÷ | |||
| Dec 31, 2023 | = | ÷ | |||
| Dec 31, 2022 | = | ÷ | |||
| Dec 31, 2021 | = | ÷ | |||
| Dec 31, 2020 | = | ÷ | |||
| Dec 29, 2019 | = | ÷ | |||
| Dec 30, 2018 | = | ÷ | |||
| Dec 31, 2017 | = | ÷ | |||
| Dec 31, 2016 | = | ÷ | |||
| Dec 31, 2015 | = | ÷ | |||
| Dec 28, 2014 | = | ÷ | |||
| Dec 29, 2013 | = | ÷ | |||
| Dec 30, 2012 | = | ÷ | |||
| Dec 31, 2011 | = | ÷ | |||
| Dec 31, 2010 | = | ÷ | |||
| Dec 31, 2009 | = | ÷ | |||
| Dec 28, 2008 | = | ÷ | |||
| Dec 30, 2007 | = | ÷ | |||
| Dec 31, 2006 | = | ÷ | |||
| Dec 31, 2005 | = | ÷ |
Based on: 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$ in millions
- Sales to Customers
- Over the observed period, sales to customers showed a generally upward trend with fluctuations. Initial growth from 50,514 million USD in 2005 to a peak around 81,581 million USD in 2018 indicates expansion. This was followed by a slight flattening in 2019 and 2020, with sales plateauing close to 82,000 million USD. Beginning in 2021, sales increased significantly, reaching a high of approximately 94,943 million USD in 2022, before experiencing a decline in 2023 to 85,159 million USD. The most recent figure for 2024 shows a partial recovery to 88,821 million USD.
- Total Assets
- Total assets increased steadily from 58,025 million USD in 2005 to a peak of 182,018 million USD in 2021, demonstrating significant growth in asset base over the years. After 2021, total assets slightly decreased to 187,378 million USD in 2022, followed by a more notable decline in 2023 to 167,558 million USD. The latest data from 2024 indicates a rebound to 180,104 million USD, although still below the recent peak levels.
- Total Asset Turnover Ratio
- The total asset turnover ratio, which measures the efficiency of using assets to generate sales, exhibited a clear downward trend from 0.87 in 2005 to about 0.49 in 2024. This decline suggests a decreasing efficiency in asset utilization over the years. Notably, it dropped from 0.87 in 2005 to below 0.6 by 2010, followed by relatively minor fluctuations around the mid-0.5 range in subsequent years. Periods of minor improvements occurred, for example, in 2018 and 2021, but the overall trajectory remains downward. The declining ratio alongside growing asset base indicates that asset expansion outpaced revenue growth, reducing turnover efficiency.
Comparison to Competitors
Johnson & Johnson, total asset turnover, long-term trends, comparison to competitors
| Johnson & Johnson | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 29, 2024 | ||||||||||||
| Dec 31, 2023 | ||||||||||||
| Dec 31, 2022 | ||||||||||||
| Dec 31, 2021 | ||||||||||||
| Dec 31, 2020 | ||||||||||||
| Dec 29, 2019 | ||||||||||||
| Dec 30, 2018 | ||||||||||||
| Dec 31, 2017 | ||||||||||||
| Dec 31, 2016 | ||||||||||||
| Dec 31, 2015 | ||||||||||||
| Dec 28, 2014 | ||||||||||||
| Dec 29, 2013 | ||||||||||||
| Dec 30, 2012 | ||||||||||||
| Dec 31, 2011 | ||||||||||||
| Dec 31, 2010 | ||||||||||||
| Dec 31, 2009 | ||||||||||||
| Dec 28, 2008 | ||||||||||||
| Dec 30, 2007 | ||||||||||||
| Dec 31, 2006 | ||||||||||||
| Dec 31, 2005 |
Based on: 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Johnson & Johnson, total asset turnover, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Johnson & Johnson | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 29, 2024 | ||
| Dec 31, 2023 | ||
| Dec 31, 2022 | ||
| Dec 31, 2021 | ||
| Dec 31, 2020 | ||
| Dec 29, 2019 | ||
| Dec 30, 2018 | ||
| Dec 31, 2017 | ||
| Dec 31, 2016 | ||
| Dec 31, 2015 | ||
| Dec 28, 2014 | ||
| Dec 29, 2013 | ||
| Dec 30, 2012 | ||
| Dec 31, 2011 | ||
| Dec 31, 2010 | ||
| Dec 31, 2009 | ||
| Dec 28, 2008 | ||
| Dec 30, 2007 | ||
| Dec 31, 2006 | ||
| Dec 31, 2005 |
Based on: 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Johnson & Johnson, total asset turnover, long-term trends, comparison to industry (health care)
| Johnson & Johnson | Health Care | |
|---|---|---|
| Dec 29, 2024 | ||
| Dec 31, 2023 | ||
| Dec 31, 2022 | ||
| Dec 31, 2021 | ||
| Dec 31, 2020 | ||
| Dec 29, 2019 | ||
| Dec 30, 2018 | ||
| Dec 31, 2017 | ||
| Dec 31, 2016 | ||
| Dec 31, 2015 | ||
| Dec 28, 2014 | ||
| Dec 29, 2013 | ||
| Dec 30, 2012 | ||
| Dec 31, 2011 | ||
| Dec 31, 2010 | ||
| Dec 31, 2009 | ||
| Dec 28, 2008 | ||
| Dec 30, 2007 | ||
| Dec 31, 2006 | ||
| Dec 31, 2005 |
Based on: 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).